Role of Steroids in Acute Infection in Rheumatoid Arthritis Patients
When a rheumatoid arthritis patient develops an acute infection, continue glucocorticoids at the current dose if already prescribed (to avoid adrenal crisis), but do NOT initiate or escalate steroids, and prioritize adding or optimizing conventional synthetic DMARDs over increasing immunosuppression. 1
Management Algorithm During Acute Infection
Immediate Actions:
- Continue existing glucocorticoid therapy at the current dose if the patient is already on steroids (abrupt discontinuation risks adrenal insufficiency) 2
- Initiate appropriate anti-infective treatment immediately - this is the priority 2
- Do NOT start new glucocorticoid therapy during active infection
- Do NOT escalate glucocorticoid doses to manage RA disease activity during infection
Disease Activity Management During Infection:
The 2021 ACR guidelines provide clear direction: for patients with a serious infection within the previous 12 months who have moderate-to-high RA disease activity, addition of conventional synthetic DMARDs is conditionally recommended over addition of biologic or targeted synthetic DMARDs 1. This same principle applies during active infection.
Furthermore, addition of/switching to DMARDs is conditionally recommended over initiation or dose escalation of glucocorticoids for managing disease activity in patients with recent serious infection 1.
Critical Evidence on Infection Risk
The relationship between glucocorticoids and infection is dose- and duration-dependent:
- Prednisone is clearly associated with increased infectious risk 3, particularly when combined with other immunosuppressants
- Glucocorticoid use increases infection risk in a cumulative manner - both dose and duration matter 4
- Infections are one of the most common causes for ICU admission in RA patients on glucocorticoids 2
Practical Steroid Management Strategy
If patient is NOT currently on steroids:
- Do not initiate during active infection
- Treat infection aggressively
- Once infection resolves, follow standard RA guidelines: glucocorticoids only as short-term bridge therapy when initiating/changing DMARDs 5
If patient IS currently on steroids:
- Continue at current dose (typically ≤5-10 mg/day prednisone equivalent)
- Monitor for adrenocortical insufficiency symptoms, especially if critically ill 2
- Do not increase dose even if RA disease activity worsens
- Plan to taper and discontinue as quickly as possible once infection clears 5
If patient requires stress-dose steroids:
- Only consider if signs of adrenal insufficiency develop in patients on chronic glucocorticoid therapy
- This is a separate indication from RA disease management 2
Key Pitfalls to Avoid
Do not confuse infection with RA flare - in systemic inflammatory conditions, distinguishing infection from disease activity is challenging 2. When in doubt, treat the infection first.
Do not use steroids to "bridge" during infection - the traditional indication for glucocorticoids as bridge therapy does NOT apply during active infection 5, 1
Do not abruptly stop chronic steroids - patients on long-term glucocorticoids (even low doses) are at risk for adrenal crisis if steroids are suddenly discontinued during physiologic stress 2
Recognize that 30% of established RA patients remain on steroids chronically 6 - despite guidelines recommending short-term use only, real-world practice shows persistent steroid use, increasing infection vulnerability
Post-Infection Management
Once the infection has resolved:
- Aggressively taper glucocorticoids to the lowest effective dose or discontinue entirely 5
- The 2026 PANLAR guidelines emphasize that toxicity associated with glucocorticoids outweighs potential benefits in chronic use 5
- Optimize DMARD therapy to achieve disease control without steroids
- Consider that very low doses (<5 mg/day) may have acceptable safety profiles if clinically necessary for long-term control 7, though cumulative risks persist